We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Researchers from the University of California San Diego (UCSD) have taken a concert hall sound diffuser and used it to develop an ultrasound device that treats conditions in the brain, such as epilepsy. Read More
Italian diagnostics startup Diadem has released study data indicating that its AlzoSure Confirm blood test can accurately identify patients with early Alzheimer's. Read More
LumiThera has announced positive 13-month findings from its LIGHTSITE III clinical study in which patients with dry age-related macular degeneration (AMD) were treated with the company’s Valeda light delivery system. Read More
San Diego, Calif.-based Biological Dynamics’ Verita blood test detected 96 percent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers in a pilot study, the company said. Read More
Nyxoah’s Genio nerve simulation system significantly reduced the severity of sleep apnea, according to the latest, nonpeer-reviewed results from a human study. Read More
The study results highlight “the potential of the assay to identify patients who may benefit from further early therapeutic intervention,” the company said. Read More
BioCircuit Technologies and Smithfield BioScience have teamed up to develop and commercialize a medical device that provides suture-less nerve repair after traumatic injuries. Read More
Salt Lake City, Utah-based ReddyPort has patented a novel device that allows patients undergoing noninvasive ventilation (NIV) to communicate. Read More
Cosmos Pharmaceuticals’ artificial intelligence (AI)-assisted GI Genius endoscopy module significantly reduced the miss rate of colorectal tumors by two times in a recent clinical trial when used in conjunction with colonoscopy. Read More
San Francisco, Calif-based prescription digital therapeutics company Blue Note Therapeutics has teamed up with clinical trial administrator Curebase for a “virtual” clinical trial to reach patients with cancer-related distress. Read More
Immunodiagnostics developer Oncimmune has inked a contract with Alphabet subsidiary Verily Life Sciences to conduct autoantibody profiling on patients who have developed long COVID-19, defined as a symptomatic case of COVID-19 that lasts for more than four weeks. Read More